econazole (spectazole) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Econazole (commonly used as the nitrate salt) is an antifungal medication of the imidazole class. It is a broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally. Sold under the brand name Ecoza among others, it is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. Econazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Econazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.   NCATS

Chemistry

  • SMILES: Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
  • InChIKey: LEZWWPYKPKIXLL-UHFFFAOYSA-N
  • Mol. Mass: 381.69
  • ALogP: 5.8
  • ChEMBL Molecules:
    econazole  
    econazole nitrate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1963 - $0.4198
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(2,4-dichloro-beta-((p-chlorobenzyl)oxy)phenethyl)imidazole | econazole | (+-)-econazole | econazole nitrate | ecostatin | ecostatin-1 | ecostatin twin pack | gyno-pevaryl | gyno-pevaryl 150 | gyno-pevaryl 1 cp pack | gyno-pevaryl once | micofugal | pevaryl | r-14827 | spectazole | sq-13050

Organizations (19)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (2)


 

Paronychia

Tinea Pedis (approved 1982)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Healthy Volunteers (Phase 1)

Onychomycosis (Phase 2)

Tinea Pedis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue